UCLA team engineers cord-blood-derived T cells with dual tumour-detection systems to target solid cancers
Researchers at UCLA report that off-the-shelf T cells made from cord blood stem cells controlled solid tumour growth in mice through two independent recognition mechanisms, while avoiding a key complication of donor-derived cell therapies.
Researchers at the University of California, Los Angeles have developed a method for generating ready-made cancer-fighting T cells from cord blood haematopoietic stem cells, according to reporting published by ScienceDaily on 11 September 2026. The engineered cells are designed with two separate tumour-detection systems, an approach intended to reduce the risk of cancer cells escaping immune recognition by losing a single surface marker.
In mouse models of solid tumours, a single dose of the cord-blood-derived T cells was reported to control tumour growth and extend survival. Importantly, the approach was described as avoiding graft-versus-host disease — a dangerous complication that can arise when donor-derived T cells attack the recipient's healthy tissues. Cord blood is an established source for allogeneic cell therapies because its immune cells are comparatively immature and less likely to trigger this response.
The work is at a preclinical stage. The specific tumour types tested, the precise engineering strategy, and the institution's research group are not detailed in the available summary reporting. No human trial data are presented. The finding is relevant to the broader field of allogeneic CAR T-cell therapy, where manufacturing scalability and the challenge of solid tumour targeting remain active areas of research.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Scientists at UCLA in the United States have found a way to make cancer-fighting immune cells — called T cells — from blood collected from umbilical cords at birth. These specially engineered cells are designed to spot tumours in two different ways, making it harder for cancer cells to hide. In experiments in mice with solid tumours, a single treatment with these cells helped control the cancer and helped the animals live longer. The approach also avoided a serious side effect called graft-versus-host disease, where donor immune cells can mistakenly attack the patient's own body. This research is at an early laboratory stage and has not yet been tested in people. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source ScienceDaily · 2026-09-11UCLA scientists turn cord blood into powerful cancer-fighting T cells